Page 40 - GALENIKA MEDICAL JOURNAL

i postojanje izolovane sistolne hipertenzije, angine pektoris pacijenata sa dijabetesom i pacijenata sa hroničnom
i koronarne, odnosno karotidne ateroskleroze, sa podjed- bubrežnom slabošću 3, 19-21 . Kod pacijenata sa hroničnom bu-
nakom efikasnošću lerkanidipina i amlodipina u hroničnoj brežnom slabošću, lerkanidipin je doveo do značajne reduk-
terapiji 3, 20 . Efikasnost lerkanidipina u regulaciji sistolne i di- cije arterijskog pritiska, ali i popravka klirensa kreatinina i
jastolne arterijske hipertenzije potvrđena je i u podgrupama smanjenja proteinurije 3, 21 .

Zaključak

Beta blokatori i kalcijumski antagonisti dokazano su efikasni i bezbjedni u svim grupama pacijenata.

Ova sveobuhvatna učinkovitost, uz optimalan profil neželjenih efekata, omogućava njihovu primjenu
u primarnoj i sekundarnoj prevenciji neželjenog kardiovaskularnog događaja, što je praćeno
povoljnim uticajem na simpatički nervni sistem uz nefroprotekciju i metaboličku neutralnost.

Abstract

Although the response to antihypertensive therapy is individual, almost all antihypertensives reduce arterial pressure by
10-15%. From the analysis of the effectiveness of antihypertensives, both in monotherapy and comedication in patients
with multiple comorbidities, through clinical studies and real-world data, it is concluded that beta blockers and calcium
channel blockers have been proven to be effective and safe in all groups of patients. This comprehensive efficacy, with an
optimal profile of side effects, results from proven efficacy in primary and secondary prevention of adverse cardiovascular
events, and impact on the sympathetic nervous system with nephroprotection and metabolic neutrality.

Keywords: antihypertensive drugs, beta-blockers, calcium antagonists, metabolic neutrality, nephroprotection

Literatura 7. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer
D, et al, on behalf of the American Diabetes Association. 10.
Cardiovascular Disease and Risk Management: Standards of Care in
1. Sudano I, Osto E, Ruschitzka F. Blood Pressure-Lowering Therapy. Diabetes-2023. Diabetes Care. 2023 Jan 1;46(Suppl 1):S158-S190.
Handb Exp Pharmacol. 2022;270:25-45. 8. Chung J, Han JK, Yang HM, Park KW, Kang HJ, Koo BK, et al; investigators
2. Sinnott SJ, Douglas IJ, Smeeth L, Williamson E, Tomlinson LA. First line for Korea Acute Myocardial Infarction Registry (KAMIR). Long-term
drug treatment for hypertension and reductions in blood pressure efficacy of vasodilating β-blocker in patients with acute myocardial
according to age and ethnicity: cohort study in UK primary care. BMJ. infarction: nationwide multicenter prospective registry. Korean J Intern
2020 Nov 18;371:m4080. Med. 2021 Mar;36(Suppl 1):S62-S71.
3. Mahfoud F, Böhm M, Bongarth CM, Bosch R, Schmieder RE, Schunkert 9. Marketou M, Gupta Y, Jain S, Vardas P. Differential Metabolic Effects
H, et al. Kommentar zu den Leitlinien (2018) der Europäischen of Beta-Blockers: an Updated Systematic Review of Nebivolol. Curr
Gesellschaft für Kardiologie (ESC) und der Europäischen Gesellschaft Hypertens Rep. 2017 Mar;19(3):22.
für Hypertonie (ESH) für das Management der arteriellen Hypertonie 10. Kuz'min OB, Belianin VV, Zhezha VV. [Nephroprotective properties
[Comments on the guidelines (2018) of the European Society of of third-generation beta-adrenoblockers]. Eksp Klin Farmakol.
Cardiology (ESC) and the European Society of Hypertension (ESH) 2014;77(3):40-3.
on the management of arterial hypertension]. Internist (Berl). 2019
Apr;60(4):424-30. 11. 11.Zepeda RJ, Castillo R, Rodrigo R, Prieto JC, Aramburu I, Brugere
4. Nascimento MM, Bernardo DRD, de Bragança AC, Massola Shimizu S, et al. Effect of carvedilol and nebivolol on oxidative stress-related
parameters and endothelial function in patients with essential
MH, Seguro AC, Volpini RA, et al. Treatment with β-blocker nebivolol hypertension. Basic Clin Pharmacol Toxicol. 2012 Nov;111(5):309-16.
ameliorates oxidative stress and endothelial dysfunction in tenofovir-
induced nephrotoxicity in rats. Front Med (Lausanne). 2022 Aug 12. Kažić T. Antagonisti kalcijuma. U: Kažić T, Ostojić M, urednici. Klinička
4;9:953749. kardiovaskularna farmakologija. V izdanje. Beograd: Integra; 2009;
643-68.
5. AlHabeeb W, Mrabeti S, Abdelsalam AAI. Therapeutic Properties of
Highly Selective β-blockers With or Without Additional Vasodilator 13. Borghi C. Lercanidipine in hypertension. Vasc Health Risk Manag.
Properties: Focus on Bisoprolol and Nebivolol in Patients With 2005;1(3):173-82.
Cardiovascular Disease. Cardiovasc Drugs Ther. 2022 Oct;36(5):959-71.
14. Barbagallo M, Barbagallo Sangiorgi G. Efficacy and tolerability of
6. de Nigris F, Mancini FP, Balestrieri ML, Byrns R, Fiorito C, Williams- lercanidipine in monotherapy in elderly patients with isolated systolic
Ignarro S, et al. Therapeutic dose of nebivolol, a nitric oxide-releasing hypertension. Aging (Milano). 2000 Oct;12(5):375-9.
beta-blocker, reduces atherosclerosis in cholesterol-fed rabbits. Nitric
Oxide. 2008 Aug;19(1):57-63.

38 DOI: 10.5937/Galmed2306034P